The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Davydov O.S.

Institute of General Pathology and Pathophysiology

Bakhtadze M.A.

Research Institute of General Pathology and Pathophysiology

Barulin A.E.

Volgograd State Medical University

Devlikamova F.I.

Kazan State Medical Academy — branch of Russian medical Academy of continuing professional education

Kalinsky P.P.

Pacific State Medical University

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Kurushina O.V.

Volgograd State Medical University

Nasonova T.I.

Sechenov First Moscow State Medical University

Teplyakova O.V.

Ural State Medical University

Churyukanov M.V.

Sechenov First Moscow State Medical University

Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution

Authors:

Davydov O.S., Bakhtadze M.A., Barulin A.E., Devlikamova F.I., Kalinsky P.P., Kukushkin M.L., Kurushina O.V., Nasonova T.I., Teplyakova O.V., Churyukanov M.V.

More about the authors

Journal: Russian Journal of Pain. 2024;22(4): 96‑102

DOI: 10.17116/pain20242204196

Read: 1100 times

Download PDF (RU)
Contact the author
Table of contents

CYCLOBENZAPRINE FOR FIBROMYALGIA MANAGEMENT FROM THE STANDPOINT OF PATHOGENESIS OF DISEASE, EVIDENCE-BASED MEDICINE AND FOREIGN CONCILIATION DOCUMENTS. EXPERT RESOLUTION
CYCLOBENZAPRINE FOR FIBROMYALGIA MANAGEMENT FROM THE STANDPOINT OF PATHOGENESIS OF DISEASE, EVIDENCE-BASED MEDICINE AND FOREIGN CONCILIATION DOCUMENTS. EXPERT RESOLUTION

To cite this article:

Davydov OS, Bakhtadze MA, Barulin AE, et al. . Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution. Russian Journal of Pain. 2024;22(4):96‑102. (In Russ.)
https://doi.org/10.17116/pain20242204196

 
 
Подписка 2025 Российский журнал боли (Russian Journal of Pain)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Cyclobenzaprine for fibromyalgia management from the standpoint of pathogenesis of disease, evidence-based medicine and foreign conciliation documents. Expert resolution.

Authors:

Davydov O.S.

Institute of General Pathology and Pathophysiology

Bakhtadze M.A.

Research Institute of General Pathology and Pathophysiology

Barulin A.E.

Volgograd State Medical University

Devlikamova F.I.

Kazan State Medical Academy — branch of Russian medical Academy of continuing professional education

Kalinsky P.P.

Pacific State Medical University

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Kurushina O.V.

Volgograd State Medical University

Nasonova T.I.

Sechenov First Moscow State Medical University

Teplyakova O.V.

Ural State Medical University

Churyukanov M.V.

Sechenov First Moscow State Medical University

Received:

08.07.2024

Accepted:

31.07.2024

Close metadata

References:

  1. Häuser W, Sarzi-Puttini P, Fitzcharles MA. Fibromyalgia syndrome: under-, over- and misdiagnosis. Clin Exp Rheumatol. 2019 Jan-Feb;(37 Suppl)116(1):90-97. Epub 2019 Feb 08. PMID: 30747096.
  2. Davydov OS, Glebov MV. Fibromyalgia. Russian Journal of Pain. 2020;18(3):66-74. (In Russ.). https://doi.org/10.17116/pain20201803166
  3. Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017 July-Aug;57(4):356-363. Epub 2017 Feb 08. PMID: 28743363. (In English, Portuguese). https://doi.org/10.1016/j.rbre.2017.01.005
  4. Storozhenko ON. Rasprostranennost’ i faktory riska sindromov fibromialgii i khronicheskoj generalizovannoj boli v populyatsii g. Ekaterinburga: Diss. … kand. med. nauk. M. 2004. (In Russ.). Accessed October 23, 2022. https://rusneb.ru/catalog/000199_000009_004060836
  5. Heidari F, Afshari M, Moosazadeh M. Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int. 2017 Sept;37(9):1527-1539. Epub 2017 Apr 26. PMID: 28447207. https://doi.org/10.1007/s00296-017-3725-2
  6. Yunus MB. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat. 2012;2012:584573. Epub 2011 Nov 17. PMID: 22191024; PMCID: PMC3236313. https://doi.org/10.1155/2012/584573
  7. Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014 Sept;34(9):1275-1280. Epub 2014 Mar 04. PMID: 24589726. https://doi.org/10.1007/s00296-014-2972-8
  8. Coskun Benlidayi I. Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases. Rheumatol Int. 2020 Jun;40(6):849-858. Epub 2020 Jan 3. PMID: 31900502. https://doi.org/10.1007/s00296-019-04506-2
  9. Ahmad J, Tagoe CE. Fibromyalgia and chronic widespread pain in autoimmune thyroid disease. Clin Rheumatol. 2014 July;33(7):885-891. Epub 2014 Jan 18. PMID: 24435355. https://doi.org/10.1007/s10067-014-2490-9
  10. Thomas C, Schneider BT, Verza CS, Fassina G, Weber LR, Moreira M, Fusinato PT, Forcelini CM. Prevalence of fibromyalgia in a Brazilian series of patients with multiple sclerosis. Arq Neuropsiquiatr. 2023 Sept;81(9):803-808. Epub 2023 Oct 04. PMID: 37793402; PMCID: PMC10550347. https://doi.org/10.1055/s-0043-1772673
  11. Coloma JL, Martínez-Zamora MA, Collado A, Gràcia M, Rius M, Quintas L, Carmona F. Prevalence of fibromyalgia among women with deep infiltrating endometriosis. Int J Gynaecol Obstet. 2019 Aug;146(2):157-163. Epub 2019 May 09. PMID: 30973964. https://doi.org/10.1002/ijgo.12822
  12. Yakkaphan P, Smith JG, Chana P, Tan HL, Ravindranath PT, Lambru G, Renton T. Temporomandibular Disorders and Fibromyalgia Prevalence: A Systematic Review and Meta-Analysis. J Oral Facial Pain Headache. 2023 Nov 17;37(3):177-193. PMID: 37975782; PMCID: PMC10664703. https://doi.org/10.11607/ofph.3260
  13. Hoffmann M, Farrell S, Colorado LH, Edwards K. Discordant dry eye disease and chronic pain: A systematic review and meta-analysis. Cont Lens Anterior Eye. 2024 June 07:102248. Epub ahead of print. PMID: 38851945. https://doi.org/10.1016/j.clae.2024.102248
  14. Slade GD, Greenspan JD, Fillingim RB, Maixner W, Sharma S, Ohrbach R. Overlap of Five Chronic Pain Conditions: Temporomandibular Disorders, Headache, Back Pain, Irritable Bowel Syndrome, and Fibromyalgia. J Oral Facial Pain Headache. 2020;34(Suppl):s15-s28. PMID: 32975538; PMCID: PMC10073941. https://doi.org/10.11607/ofph.2581
  15. de Tommaso M, Sardaro M, Serpino C, Costantini F, Vecchio E, Prudenzano MP, Lamberti P, Livrea P. Fibromyalgia comorbidity in primary headaches. Cephalalgia. 2009 Apr;29(4):453-464. Epub 2009 Dec 15. PMID: 19170692. https://doi.org/10.1111/j.1468-2982.2008.01754.x
  16. Aoyagi K, He J, Nicol AL, Clauw DJ, Kluding PM, Jernigan S, Sharma NK. A Subgroup of Chronic Low Back Pain Patients With Central Sensitization. Clin J Pain. 2019 Nov;35(11):869-879. PMID: 31408011; PMCID: PMC7197191. https://doi.org/10.1097/AJP.0000000000000755
  17. Johnson CM, Makai GEH. Fibromyalgia and Irritable Bowel Syndrome in Female Pelvic Pain. Semin Reprod Med. 2018 Mar;36(2):136-142. Epub 2018 Dec 19. PMID: 30566979. https://doi.org/10.1055/s-0038-1676090
  18. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed. 2007 Aug;78(2):88-95. PMID: 17933276.
  19. Hass DR, Muraroto E, Von Der Heyde M, Skare TL. Prevalence of fibromyalgia in depressive patients and its influence in the degree of depression and quality of life. Asia Pac Psychiatry. 2014 Dec;6(4):458-459. PMID: 25425067. https://doi.org/10.1111/appy.12159
  20. Alciati A, Atzeni F, Salaffi F, Sarzi-Puttini P. Onset and temporal sequencing patterns of comorbidity between lifetime major depression, panic disorder and fibromyalgia. Clin Exp Rheumatol. 2022 June;40(6):1194-1201. Epub 2022 June 13. PMID: 35699055. https://doi.org/10.55563/clinexprheumatol/ryp027
  21. Bernik M, Sampaio TP, Gandarela L. Fibromyalgia comorbid with anxiety disorders and depression: combined medical and psychological treatment. Curr Pain Headache Rep. 2013 Sept;17(9):358. PMID: 23904203. https://doi.org/10.1007/s11916-013-0358-3
  22. Buskila D, Ablin JN, Ben-Zion I, Muntanu D, Shalev A, Sarzi-Puttini P, Cohen H. A painful train of events: increased prevalence of fibromyalgia in survivors of a major train crash. Clin Exp Rheumatol. 2009 Sept-Oct;27(5 Suppl 56):S79-S85. PMID: 20074445.
  23. Lawrence-Wolff KM, Higgs JB, Young-McCaughan S, Mintz J, Foa EB, Resick PA, Kelly KM, Maurer DM, Borah AM, Yarvis JS, Litz BT, Hildebrand BA, Williamson DE, Peterson AL; STRONG STAR Consortium. Prevalence of Fibromyalgia Syndrome in Active-Duty Military Personnel. Arthritis Care Res (Hoboken). 2023 Mar;75(3):667-673. Epub 2022 Oct 31. PMID: 34606694. https://doi.org/10.1002/acr.24801
  24. Akkaya H, Güntürk EE, Kaydok E, Özdemir B. Determination of the increased risk of developing atrial fibrillation in fibromyalgia syndrome. Adv Rheumatol. 2020 Jan 30;60(1):14. PMID: 32000854. https://doi.org/10.1186/s42358-020-0112-6
  25. Tseng CH, Chen JH, Wang YC, Lin MC, Kao CH. Increased Risk of Stroke in Patients With Fibromyalgia: A Population-BASED Cohort Study. Medicine (Baltimore). 2016 Feb;95(8):e2860. PMID: 26937918; PMCID: PMC4779015. https://doi.org/10.1097/MD.0000000000002860
  26. Gill H, Perez CD, Gill B, El-Halabi S, Lee Y, Lipsitz O, Park C, Mansur RB, Rodrigues NB, McIntyre RS, Rosenblat JD. The Prevalence of Suicidal Behaviour in Fibromyalgia Patients. Prog Neuropsychopharmacol Biol Psychiatry. 2021 June 08;108:110078. Epub 2020 Aug 24. PMID: 32853715. https://doi.org/10.1016/j.pnpbp.2020.110078
  27. Smith D, Wilkie R, Uthman O, Jordan JL, McBeth J. Chronic pain and mortality: a systematic review. PLoS One. 2014 June 05;9(6):e99048. PMID: 24901358; PMCID: PMC4047043. https://doi.org/10.1371/journal.pone.0099048
  28. Fitzcharles MA, Ste-Marie PA, Rampakakis E, Sampalis JS, Shir Y. Disability in Fibromyalgia Associates with Symptom Severity and Occupation Characteristics. J Rheumatol. 2016 May;43(5):931-936. Epub 2016 Mar 15. PMID: 26980580. https://doi.org/10.3899/jrheum.151041
  29. Nasonova TI, Bakhtadze MA, Mukhametzyanova AKh, Isaikin AI. The Revised Fibromyalgia Impact Questionnaire: linguistic adaptation of the Russian version. Russian Journal of Pain. 2023;21(1):47-51. (In Russ.). https://doi.org/10.17116/pain20232101147
  30. D’Onghia M, Ciaffi J, Ruscitti P, Cipriani P, Giacomelli R, Ablin JN, Ursini F. The economic burden of fibromyalgia: A systematic literature review. Semin Arthritis Rheum. 2022 Oct;56:152060. Epub 2022 July 03. PMID: 35849890. https://doi.org/10.1016/j.semarthrit.2022.152060
  31. Boonen A, van den Heuvel R, van Tubergen A, Goossens M, Severens JL, van der Heijde D, van der Linden S. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis. 2005 Mar;64(3):396-402. Epub 2004 July 22. PMID: 15271773; PMCID: PMC1755408. https://doi.org/10.1136/ard.2003.019711
  32. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021 Apr 09;22(8):3891. PMID: 33918736; PMCID: PMC8068842. https://doi.org/10.3390/ijms22083891
  33. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism. 2008;37(6):339-352.  https://doi.org/10.1016/j.semarthrit.2007.09.003
  34. Bradley LA. Pathophysiology of fibromyalgia. The American Journal of Medicine. 2009;122(12 Suppl):22-30.  https://doi.org/10.1016/j.amjmed.2009.09.008
  35. Casale R, Sarzi-Puttini P, Botto R, Alciati A, Batticciotto A, Marotto D, Torta R. Fibromyalgia and the concept of resilience. Clin Exp Rheumatol. 2019 Jan-Feb;(37 Suppl)116(1):105-113. Epub 2019 Feb 08. PMID: 30747098.
  36. Häuser W, Perrot S, Clauw DJ, Fitzcharles MA. Unravelling Fibromyalgia-Steps Toward Individualized Management. J Pain. 2018 Feb;19(2):125-134. Epub 2017 Sept 21. PMID: 28943233. https://doi.org/10.1016/j.jpain.2017.08.009
  37. Clauw D. Time to Stop the Fibromyalgia Criteria Wars and Refocus on Identifying and Treating Individuals With This Type of Pain Earlier in Their Illness. Arthritis Care Res (Hoboken). 2021 May;73(5):613-616. PMID: 32248650. https://doi.org/10.1002/acr.24198
  38. Häuser W, Clauw DJ, Wolfe F, Sarzi-Puttini P, Ablin JN, Usui C, Littlejohn GO, Morlion B, Kosek E, Fors EA, Øien Forseth KM, Fitzcharles MA. Concerns about the taxonomy, definition and coding of fibromyalgia syndrome in ICD-11: the potential for negative consequences for patient care and research. Clin Exp Rheumatol. 2022 June;40(6):1073-1075. Epub 2022 June 09. PMID: 35699071. https://doi.org/10.55563/clinexprheumatol/3bt9qx
  39. Kang JH, Choi SE, Park DJ, Lee SS. Disentangling Diagnosis and Management of Fibromyalgia. J Rheum Dis. 2022 Jan 01;29(1):4-13. PMID: 37476701; PMCID: PMC10324920. https://doi.org/10.4078/jrd.2022.29.1.4
  40. Choy E, Perrot S, Leon T, Kaplan J, Petersel D, Ginovker A, Kramer E. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res. 2010 Apr 26;10:102. PMID: 20420681; PMCID: PMC2874550. https://doi.org/10.1186/1472-6963-10-102
  41. Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015 Sept 17;10(9):e0138024. PMID: 26379048; PMCID: PMC4575027. https://doi.org/10.1371/journal.pone.0138024
  42. Nasonova TI, Parfenov VA, Mukhametzyanova AKh. Typical practice for managing patients with fibromyalgia. Consilium Medicum. 2022;24(11):796-799. (In Russ.). https://doi.org/10.26442/20751753.2022.11.202013
  43. Van Wilgen CP, Ucles-Juarez R, Krutko D, Li Y, Polli A, Syed A, Zampese S, Reis FJJ, de Zeeuw J. Knowledge on cause, clinical manifestation and treatment for fibromyalgia among medical doctors: A worldwide survey. Pain Pract. 2024 Apr;24(4):620-626. Epub 2023 Dec 29. PMID: 38156436. https://doi.org/10.1111/papr.13339
  44. Nasonova TI, Bakhtadze MA, Mukhametzyanova AKh, Isaikin AI. Fibromyalgia rapid screening tool: linguistic adaptation of the Russian version. Russian Journal of Pain. 2022;20(3):16-20. (In Russ.). https://doi.org/10.17116/pain20222003116
  45. Häuser W, Jung E, Erbslöh-Möller B, Gesmann M, Kühn-Becker H, Petermann F, Langhorst J, Thoma R, Weiss T, Wolfe F, Winkelmann A. The German fibromyalgia consumer reports — a cross-sectional survey. BMC Musculoskelet Disord. 2012 May 18;13:74. PMID: 22607517; PMCID: PMC3444387. https://doi.org/10.1186/1471-2474-13-74
  46. Teplyakova OV, Popov AA, Volkova LI, Sarapulova AV. Fibromyalgia: clinical presentations and variants of the disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2):45-51. (In Russ.). https://doi.org/10.14412/1996-7012-2020-2-45-51
  47. Liu Y, Qian C, Yang M. Treatment Patterns Associated with ACR-Recommended Medications in the Management of Fibromyalgia in the United States. J Manag Care Spec Pharm. 2016 Mar;22(3):263-271. PMID: 27003556; PMCID: PMC10398128. https://doi.org/10.18553/jmcp.2016.22.3.263
  48. Katz WA, Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: Review of a decade of clinical experience. Clinical Therapeutics. 1988;10(2):216-228. 
  49. Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. European Journal of Pharmacology. 1996;311(1):29-35. 
  50. Long-term Use of Cyclobenzaprine for Pain: A Review of the Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Feb 23. Summary of evidence. https://www.ncbi.nlm.nih.gov/books/NBK279660
  51. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988 Dec;31(12):1535-1542. PMID: 3058130.
  52. Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004 Feb 15;51(1):9-13. PMID: 14872449. https://doi.org/10.1002/art.20076
  53. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994 Jan;37(1):32-40. PMID: 8129762. https://doi.org/10.1002/art.1780370106
  54. Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011 Dec;38(12):2653-2663. Epub 2011 Sept 01. PMID: 21885490. https://doi.org/10.3899/jrheum.110194
  55. Lederman S, Arnold LM, Vaughn B, Kelley M, Sullivan GM. Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2359-2368. Epub 2023 July 04. PMID: 37165930. https://doi.org/10.1002/acr.25142
  56. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017 Feb;76(2):318-328. Epub 2016 July 04. PMID: 27377815. https://doi.org/10.1136/annrheumdis-2016-209724
  57. Sommer C, Alten R, Bär KJ, Bernateck M, Brückle W, Friedel E, Henningsen P, Petzke F, Tölle T, Üçeyler N, Winkelmann A, Häuser W. Medikamentöse Therapie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten [Drug therapy of fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles]. Schmerz. 2017 June;31(3):274-284. PMID: 28493231. (In German). https://doi.org/10.1007/s00482-017-0207-0
  58. Ariani A, Bazzichi L, Sarzi-Puttini P, Salaffi F, Manara M, Prevete I, Bortoluzzi A, Carrara G, Scirè CA, Ughi N, Parisi S. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia Best practices based on current scientific evidence. Reumatismo. 2021 Aug 03;73(2):89-105. PMID: 34342210. https://doi.org/10.4081/reumatismo.2021.1362
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.